Last edition
News about
Opportunities and challenges need to be harnessed in digital ecosystem
A vibrant digital health ecosystem can not only ease access to health services, making ubiquitous and streamlined, but also reduce out of pocket expenses in the long term and healthcare industry players should start assessing the opportunities and risks they could face, say experts from data and analytics major IQVIA.
3D model created for rare neuromuscular disorder
Scientists have created a bioengineered 3-D model that mimics the biology of two rare diseases. The researchers used the 'tissue chip' model to show how a drug could potentially treat the diseases, providing data for a drug company's FDA submission for authorization for clinical testing.
3 NODE - 302 data provided by Milestone Pharma
Milestone Pharma presents data from phase 3 NODE-302 study of etripamil to treat paroxysmal supraventricular tachycardia
New patent grant to OSE Immunotherapeutics by EPO
OSE Immunotherapeutics receives European patent covering novel myeloid immune checkpoint target, CLEC-1 for cancer treatment
Duchenne gene therapy trials resumed
Pfizer is set to resume its late-stage clinical trials of a treatment for Duchenne muscular dystrophy after stopping in December because of a clinical hold.
Kelonia Therapeutics is the newest biotech to hit the pharma scene after receiving $50 million in start-up money.
The U.S. FDA has accepted Fennec Pharmaceuticals resubmitted new drug application (NDA) for Pedmark, a drug aimed at preventing hearing loss in children who receive platinum-based chemothera
EMA reviews gene therapy for Haemophilia B
EMA (European Medicines Agency) has started reviewing the CSL Behring's MAA for gene therapy etranacogene dezaparvovec (EtranaDez), for the patients getting treatment for Haemophila B.
PET blister lidding solution formulated by Huhtamaki
Finland's Huhtamaki comes up with a sustainable solution for pharmaceutical and healthcare industry around the world
Schizophrenia and bi-polar drug gets FDA approval
The U.S. FDA has approved a new drug from BioXcel used to treat patients with schizophrenia or bipolar I or II disorder. BioXcel?s drug Igalmi was developed using the company?s artificial intelligence platform, marking a big step for the technology in the pharmaceutical industry, according to BioXcel.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy